Meanwhile, MUC16 has been extensively researched as a biomarker in ovarian, pancreatic, and bladder cancer, with the clinical application of CA125 in ovarian cancer [81], where MUC16 is FDA-approved as a biomarker for monitoring ovarian cancer recurrence [82]. This evidence concerns the gene MUC16 and urinary bladder carcinoma.